Next Article in Journal
Inactivation of Caliciviruses
Next Article in Special Issue
The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells
Previous Article in Journal
Cell Penetration Properties of a Highly Efficient Mini Maurocalcine Peptide
Previous Article in Special Issue
Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?
Pharmaceuticals 2013, 6(3), 340-357; doi:10.3390/ph6030340
Review

A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches

Received: 16 February 2013; in revised form: 9 March 2013 / Accepted: 11 March 2013 / Published: 19 March 2013
(This article belongs to the Special Issue Aptamer-Based Therapeutics)
View Full-Text   |   Download PDF [458 KB, uploaded 19 March 2013]   |   Browse Figures
Abstract: The potential to emulate or enhance antibodies with nucleic acid aptamers while lowering costs has prompted development of new aptamer-protein, siRNA, drug, and nanoparticle conjugates. Specific focal points of this review discuss DNA aptamers covalently bound at their 3' ends to various proteins for enhanced stability and greater pharmacokinetic lifetimes in vivo. The proteins can include Fc tails of IgG for opsonization, and the first component of complement (C1q) to trigger complement-mediated lysis of antibiotic-resistant Gram negative bacteria, cancer cells and possibly some parasites during vulnerable stages. In addition, the 3' protein adduct may be a biotoxin, enzyme, or may simply be human serum albumin (HSA) or a drug known to bind HSA, thereby retarding kidney and other organ clearance and inhibiting serum exonucleases. In this review, the author summarizes existing therapeutic aptamer conjugate categories and describes his patented concept for PCR-based amplification of double-stranded aptamers followed by covalent attachment of proteins or other agents to the chemically vulnerable overhanging 3' adenine added by Taq polymerase. PCR amplification of aptamers could dramatically lower the current $2,000/gram cost of parallel chemical oligonucleotide synthesis, thereby enabling mass production of aptamer-3'-protein or drug conjugates to better compete against expensive humanized monoclonal antibodies.
Keywords: antibiotic-resistant; aptamer; cancer; complement; DNA; nanoparticle; opsonization; PCR; SELEX; siRNA antibiotic-resistant; aptamer; cancer; complement; DNA; nanoparticle; opsonization; PCR; SELEX; siRNA
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Bruno, J.G. A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches. Pharmaceuticals 2013, 6, 340-357.

AMA Style

Bruno JG. A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches. Pharmaceuticals. 2013; 6(3):340-357.

Chicago/Turabian Style

Bruno, John G. 2013. "A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches." Pharmaceuticals 6, no. 3: 340-357.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert